Table 2.
Effects of various variables on anthracycline-induced subclinical cardiotoxicity in DLBCL patients completed 3 cycles chemotherapy
| Characteristics | OR (95%CI) | P-value |
|---|---|---|
| Age, per 1 year | 1.000 (0.964, 1.036) | 0.982 |
| Male, yes versus no | 0.833 (0.316, 2.201) | 0.713 |
| BMI, per 1 kg/m2 | 1.219 (1.033,1.438) | 0.019 |
| Smoking, yes versus no | 3.304 (1.067, 10.226) | 0.038 |
| GLS, per -1% | 1.200 (0.949, 1.517) | 0.129 |
| E, per 1 cm/s | 1.030 (0.991, 1.070) | 0.138 |
| e’, per 1 cm/s | 1.258 (0.980, 1.614) | 0.071 |
| LDL-C, per 1 mmol/L | 2.016 (0.992,4.095) | 0.053 |
| HDL-C, per 1 mmol/L | 0.371 (0.082, 1.683) | 0.199 |
| NT-proBNP, per 1 ng/L | 0.993 (0.986,1.000) | 0.066 |
| TG, per 1 mmol/L | 1.806 (0.942,3.462) | 0.075 |
Bold values indicate statistical significance
BMI Body mass index, cTnT cardiac troponin T, Cr Creatinine, FS Fractional shortening, GLS Global longitudinal peak systolic strain, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, NT-proBNP N terminal-pro brain natriuretic peptide, TG Total cholesterol